SCHEMBL19425477

SCHEMBL19425477

Cc1cccc(NC(=O)c2c(O)c(O)cc3c(O)c(-c4c(C)cc5c(C(=O)Nc6cccc(C(F)(F)F)c6)c(O)c(O)cc5c4O)c(C)cc23)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 1/20 0.56
KMT2A Q03164 1/20 0.56
BCL2L1 Q07817 6/20 0.55
KCNK3 O14649 1/20 0.52
KCNK9 Q9NPC2 1/20 0.52
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPY5R Q15761 1/20 0.48
P2RX1 P51575 1/20 0.48
RXFP1 Q9HBX9 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
BCL2 P10415 4/20 0.47
MCL1 Q07820 4/20 0.47
BCL2A1 Q16548 2/20 0.47
MAPT P10636 1/20 0.46
IDH1 O75874 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3473744 0.96 BCL2L1 (0.60) MEN1HTTRAB9AKMT2ABCL2L1
SCHEMBL3474740 0.80 BCL2L1 (0.67) BCL2L1BCL2MCL1BCL2A1
SCHEMBL19420192 0.78 BCL2L1 (0.64) BCL2L1BCL2MCL1BCL2A1
SCHEMBL10192109 0.73 KMT2A (0.74) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL12764063 0.72 MEN1 (1.00) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL15847043 0.72 KCNK3 (0.92) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL3472615 0.72 BCL2L1 (0.67) BCL2L1KDM4EBCL2MCL1BCL2A1
SCHEMBL14394718 0.72 P2RX1 (0.78) MEN1HTTRAB9AKMT2AKCNK3
SCHEMBL352825 0.72 BCL2L1 (1.00) BCL2L1BCL2MCL1BCL2A1
SCHEMBL9080921 0.72 MEN1 (0.66) MEN1HTTRAB9AKMT2AKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease UNITY BIOTECHNOLOGY, INC. (US) 2019-02-05 US disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 MEN1 3416/4885HTT 356/4885RAB9A 1412/4885
US-10195213-B2 Chemical entities that kill senescent cells for use in treating age-related disease TP53, CDKN1A, GLA MEN1 2434/4885HTT 368/4885RAB9A 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.